Ocugen, Inc. 8-K

What Happened

• Ocugen, Inc. announced on March 24, 2026 that it released topline 12‑month data from its Phase 2 ArMaDa clinical trial evaluating OCU410, a modifier gene therapy, for geographic atrophy secondary to dry age‑related macular degeneration (GA due to dry AMD).
• The company filed a press release and presentation materials (Exhibits 99.1–99.3) with this Form 8‑K and scheduled a conference call and webcast for 8:00 a.m. EDT on March 24, 2026 to discuss the full dataset. Presentation slides will be posted on Ocugen’s website (www.ocugen.com).

Key Details

• Trial & drug: Phase 2 ArMaDa trial evaluating OCU410 for geographic atrophy secondary to dry AMD.
• Data timing: Topline 12‑month clinical data announced March 24, 2026.
• Investor event: Conference call and webcast scheduled for 8:00 a.m. EDT on March 24, 2026 to review full data.
• Filings: Press release and two sets of presentation materials are filed as Exhibits 99.1–99.3 to the 8‑K.

Why It Matters

• Clinical data readouts are major milestones for biotech companies; this topline 12‑month Phase 2 data is material to Ocugen’s clinical progress for a potential treatment of geographic atrophy.
• The webcast and posted presentations give investors and analysts the first opportunity to review the full dataset and management commentary, which can influence investor assessment of Ocugen’s pipeline value and development timeline.